학술논문
367PD - Early FDG-PET response correlates with dose and clinical efficacy in patients with microsatellite stable (MSS) metastatic CRC (mCRC) treated with the CEA-CD3 T-cell bispecific antibody plus atezolizumab
Document Type
Abstract
Author
Source
In Annals of Oncology September 2017 28 Supplement 5:v122-v123
Subject
Language
ISSN
0923-7534